Postoperative PainNCT07653932
Perioperative Quantitative Sensory Testing and Incision Pain Mapping in Thoracic Surgery
An observational study of Postoperative Pain and Chronic Postsurgical Pain, run by Tongji Hospital at 1 site in China.
Trial summary
Postoperative pain remains a common and clinically important burden after thoracic surgery and may progress to chronic postsurgical pain. Conventional pain assessment mainly relies on patient-reported pain intensity and analgesic consumption, which may not fully capture peri-incisional sensory abnormalities… Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Postoperative Pain, Chronic Postsurgical Pain, Thoracic Surgery
- What is being tested?
- Perioperative QST and incision pain mapping assessment
- How many people
- 46 participants
- Where
- 1 siteChina
- Study dates
- 8 Jun 2026to 28 Feb 2027
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients scheduled to undergo elective thoracoscopic or robotic-assisted lung resection at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Who may be able to join
- Male
- Scheduled to undergo elective thoracoscopic or robotic-assisted lung resection.
- American Society of Anesthesiologists physical status I to III.
- Able to understand and communicate adequately and to complete study questionnaires independently or with assistance from study staff.
- Willing to undergo QST assessment, perioperative venous blood sampling, and postoperative follow-up.
- Able and willing to provide written informed consent.
Who cannot join
- Definite chronic chest wall, shoulder, back, or upper limb pain with an average 2. Numeric Rating Scale score of 3 or higher during the preceding week.
- 3. Definite painful neuropathic disease or long-term use of opioids or other analgesics for more than 2 weeks.
- 4. Peripheral neuropathy, spinal cord disease, or other neurological disease that may substantially interfere with interpretation of QST results.
- 5. Severe cognitive impairment, psychiatric disorder, communication disorder, or inability to complete questionnaires and QST assessments.
- 6. Active infection, active autoimmune disease, or other disease condition that may substantially affect inflammatory protein measurements.
- 7. Emergency surgery, conversion to open thoracotomy, extensive chest wall resection, or severe intraoperative complications.
- 8. Any condition that, in the opinion of the investigator, makes the participant unsuitable for continued participation in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Tongji Hospital
Wuhan, Hubei, 430030
Wei Ping, Dr., 8613437101581, pingwei@tjh.tjmu.edu.cn
About this study
Official title: Perioperative Pain Phenotyping and Incision Pain Mapping Using Quantitative Sensory Testing in Patients Undergoing Thoracoscopic or Robotic-assisted Lung Resection: A Prospective Observational Pilot Cohort Study
Postoperative pain remains a common and clinically important burden after thoracic surgery and may progress to chronic postsurgical pain. Conventional pain assessment mainly relies on patient-reported pain intensity and analgesic consumption, which may not fully capture peri-incisional sensory abnormalities, mechanical hyperalgesia, or central sensitization.
This prospective observational pilot cohort study aims to evaluate the feasibility and acceptability of perioperative quantitative sensory testing (QST) and incision pain mapping in adult patients undergoing elective thoracoscopic or robotic-assisted lung resection. Participants will undergo baseline assessment before surgery, serial postoperative pain assessments during the first 72 hours, QST and mechanical hyperalgesia pain mapping at 48-72 hours after surgery, and follow-up assessments at discharge, 1 month, and 3 months after surgery.
Read more
The primary feasibility outcomes include recruitment rate, QST completion rates, follow-up completion rates, QST-related discontinuation rate, study-related adverse events, and data completeness. The main clinical mechanistic outcome is the area of peri-incisional mechanical hyperalgesia at 48-72 hours after surgery. Secondary outcomes include acute postoperative pain intensity, pain burden over 72 hours, opioid consumption, quality of recovery, QST changes, pain-map characteristics, and chronic postsurgical pain at 3 months.
This study will not assign or modify therapeutic interventions. All anesthetic, surgical, and analgesic management will be determined by the routine clinical care team. The study is expected to provide feasibility data, preliminary effect estimates, and mechanistic information for future larger perioperative pain studies.
Read the detailed description
This is a single-center, prospective, observational pilot cohort study conducted in adult patients scheduled to undergo elective thoracoscopic or robotic-assisted lung resection. The study is designed to characterize perioperative pain phenotypes using standardized quantitative sensory testing (QST), incision-centered mechanical hyperalgesia pain mapping, serial pain intensity assessments, analgesic exposure, psychological and sleep-related questionnaires, and exploratory inflammatory or plasma biomarker measurements.
Eligible participants will provide written informed consent before surgery. Baseline assessments will be performed 1-3 days before surgery and will include demographic and clinical data collection, baseline pain history, psychological and sleep-related questionnaires, preoperative QST, and blood sampling. QST will assess sensory function in the surgical-side thoracic region, contralateral mirror region, and a remote control site where applicable.
During the first 72 hours after surgery, resting and movement-related numeric rating scale pain scores will be collected at prespecified time points, together with perioperative anesthetic, regional block, surgical, analgesic, and recovery-related information. Opioid consumption will be converted to morphine milligram equivalents.
At 48-72 hours after surgery, participants will undergo core postoperative QST and incision-centered mechanical pain mapping. The pain map will be generated around the incision or main port site in eight radial directions. Standardized mechanical stimulation will be applied from normal surrounding skin toward the incision, and boundary points will be marked when the participant reports a transition from normal sensation to increased pain, sharpness, burning, or abnormal discomfort. These boundary points will be connected to estimate the area of mechanical hyperalgesia.
Additional assessments will be performed before discharge, at 1 month, and at 90 ± 14 days after surgery. Follow-up assessments will evaluate persistent pain, pain intensity, pain interference, neuropathic pain features, QST changes, pain-map characteristics, quality of recovery, and exploratory blood biomarkers. Chronic postsurgical pain will be assessed at 3 months after surgery and defined as new or worsened pain related to the surgical area, persisting for at least 3 months after surgery, and not better explained by other causes.
The study will not assign any therapeutic intervention. Surgical technique, anesthetic management, regional analgesia, postoperative analgesia, chest tube management, and perioperative care will follow routine clinical practice. Key perioperative variables will be prospectively collected and considered as potential confounders in statistical analyses.
- Conditions
- Postoperative Pain, Chronic Postsurgical Pain, Thoracic Surgery, Lung Resection, Mechanical Hyperalgesia, Central Sensitization
- Being tested
- Perioperative QST and incision pain mapping assessment
- Keywords
- Quantitative sensory testing, QST, Incision pain mapping, Thoracoscopic surgery, Perioperative pain phenotype
- Medical subject headings
- Pain, Postoperative, Hyperalgesia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Perioperative QST and incision pain mapping assessmentOther
Participants will undergo non-invasive perioperative quantitative sensory testing and incision-centered mechanical pain mapping at prespecified time points. These assessments are observational and will not determine or modify clinical anesthesia, analgesia, or surgical management.
| Study group | Role | What they receive |
|---|---|---|
| Elective Thoracoscopic or Robotic-assisted Lung Resection Cohort | Adult patients scheduled for elective thoracoscopic or robotic-assisted lung resection will be enrolled and followed prospectively from the preoperative period to 3 months after surgery. Participants will undergo observational assessments including questionnaires, quantitative sensory testing, peri-incisional mechanical hyperalgesia pain mapping, serial postoperative pain assessments, analgesic exposure recording, and exploratory blood sampling. No therapeutic intervention will be assigned by the investigators. Receives: Other: Perioperative QST and incision pain mapping assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recruitment Rate
Proportion of eligible patients who provide written informed consent and are enrolled in the study.
Measured: Baseline
Completion Rate of Baseline Quantitative Sensory Testing
Proportion of enrolled participants who complete the planned baseline QST assessment before surgery.
Measured: Preoperative period, 1 to 3 days before surgery
Completion Rate of Postoperative QST and Incision Pain Mapping
Proportion of enrolled participants who complete the core postoperative QST assessment and incision-centered mechanical hyperalgesia pain mapping.
Measured: 48 to 72 hours after surgery
Completion Rate of 1-month Follow-up
Proportion of enrolled participants who complete the planned 1-month postoperative follow-up assessment.
Measured: 1 month after surgery
Completion Rate of 3-month Pain Outcome Follow-up
Proportion of enrolled participants who complete the primary 3-month postoperative pain outcome assessment.
Measured: 90 ± 14 days after surgery
QST-related Discontinuation Rate
Proportion of participants who discontinue QST or pain mapping prematurely because of pain intolerance, fatigue, anxiety, or other participant-related reasons.
Measured: From baseline assessment to 3 months after surgery
Study-related Adverse Event Rate
Proportion of participants with study-related adverse events, including marked discomfort, transient pain exacerbation, local discomfort related to QST or pain mapping, or adverse events related to blood sampling.
Measured: From baseline assessment to 3 months after surgery
Data Completeness of Key Study Variables
Proportion of missing data for key variables
Measured: From baseline assessment to 3 months after surgery
Secondary outcomes (19)
Movement-related Pain Intensity During the First 72 Hours After Surgery
Movement-related pain intensity measured using an 11-point Numeric Rating Scale during turning in bed or active mobilization, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Measured: 1, 6, 12, 18, 24, 32, 40, 48, 60, and 72 hours after surgery
Resting Pain Intensity During the First 72 Hours After Surgery
Resting pain intensity measured using an 11-point Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Measured: 1, 6, 12, 18, 24, 32, 40, 48, 60, and 72 hours after surgery
Area of Peri-incisional Mechanical Hyperalgesia
Area of mechanical hyperalgesia around the surgical incision or main port site, measured in square centimeters using standardized incision-centered mechanical pain mapping.
Measured: 48 to 72 hours after surgery
Area Under the Curve of Resting Pain Scores
Cumulative resting pain burden calculated as the area under the curve of serial resting Numeric Rating Scale pain scores during the first 72 postoperative hours.
Measured: 0 to 72 hours after surgery
Area Under the Curve of Movement-related Pain Scores
Cumulative movement-related pain burden calculated as the area under the curve of serial movement-related Numeric Rating Scale pain scores during the first 72 postoperative hours
Measured: 0 to 72 hours after surgery
Cumulative Opioid Consumption
Total postoperative opioid consumption during the first 72 hours after surgery, converted to morphine milligram equivalents.
Measured: 0 to 72 hours after surgery
Quality of Recovery-15 Score
Postoperative recovery quality assessed using the 15-item Quality of Recovery questionnaire. Higher scores indicate better recovery.
Measured: 72 hours after surgery and before discharge
Analgesia-related Adverse Effects
Incidence of analgesia-related adverse effects, including postoperative nausea and vomiting, excessive sedation, dizziness, or other analgesia-related symptoms.
Measured: 0 to 72 hours after surgery
Time to First Ambulation
Time from the end of surgery to the first documented postoperative ambulation.
Measured: Perioperative
Chest Tube Duration
Duration of postoperative chest tube drainage, measured in hours or days.
Measured: Perioperative
Postoperative Length of Hospital Stay
Number of days from surgery to hospital discharge.
Measured: Perioperative
Perioperative Complications
Incidence of perioperative complications recorded during hospitalization
Measured: Perioperative
Change in Quantitative Sensory Testing Parameters
Changes in QST parameters measured at the surgical-side thoracic region, contralateral mirror region, and remote control site when applicable.
Measured: Baseline, 48 to 72 hours after surgery, 1 month after surgery, and 90 ± 14 days after surgery
Maximum Radius of Peri-incisional Pain Map
Maximum radial distance from the incision or main port site to the boundary of mechanical hyperalgesia.
Measured: 48 to 72 hours after surgery, 1 month after surgery, and 90 ± 14 days after surgery
Minimum Radius of Peri-incisional Pain Map
Minimum radial distance from the incision or main port site to the boundary of mechanical hyperalgesia.
Measured: 48 to 72 hours after surgery, 1 month after surgery, and 90 ± 14 days after surgery
Incidence of Persistent Pain at 1 Month
Proportion of participants reporting pain related to the surgical area at 1 month after surgery.
Measured: 1 month after surgery
Incidence of Chronic Postsurgical Pain at 3 Months
Proportion of participants with new or worsened pain related to the surgical area persisting at 3 months after surgery and not better explained by other causes.
Measured: 90 ± 14 days after surgery
Pain Interference at 3 Months
Pain-related interference with daily activity, sleep, and function assessed using the Brief Pain Inventory-short form.
Measured: 90 ± 14 days after surgery
Neuropathic Pain Features at 3 Months
Neuropathic pain symptoms, such as numbness, burning pain, electric shock-like pain, or touch-evoked pain, assessed using the DN4 questionnaire and symptom interview.
Measured: 90 ± 14 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start8 Jun 2026 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- More trials run by Tongji HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 46 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Tongji Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhang Ni, Tongji Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07653932
- Sponsor's protocol ID
- TJ-IRB202605020
- Status last verified
- Jun 2026
- First submitted
- 3 Jun 2026
- Last updated
- 17 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perioperative Pain Phenotyping and Incision Pain Mapping Using Quantitative Sensory Testing in Patients Undergoing Thoracoscopic or Robotic-assisted Lung Resection: A Prospective Observational Pilot Cohort Study
- ClinicalTrials.gov ID
- NCT07653932
- Acronym / sponsor ID
- TJ-IRB202605020
- Conditions
- Postoperative Pain, Chronic Postsurgical Pain, Thoracic Surgery, Lung Resection, Mechanical Hyperalgesia, Central Sensitization
- Keywords
- Quantitative sensory testing, QST, Incision pain mapping, Thoracoscopic surgery, Perioperative pain phenotype
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 46 participants (estimated)
- Lead sponsor
- Tongji HospitalUniversity, hospital or other
- Study start
- 8 Jun 2026 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 17 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Postoperative pain remains a common and clinically important burden after thoracic surgery and may progress to chronic postsurgical pain. Conventional pain assessment mainly relies on patient-reported pain intensity and analgesic consumption, which may not fully capture peri-incisional sensory abnormalities, mechanical hyperalgesia, or central sensitization.
This prospective observational pilot cohort study aims to evaluate the feasibility and acceptability of perioperative quantitative sensory testing (QST) and incision pain mapping in adult patients undergoing elective thoracoscopic or robotic-assisted lung resection. Participants will undergo baseline assessment before surgery, serial postoperative pain assessments during the first 72 hours, QST and mechanical hyperalgesia pain mapping at 48-72 hours after surgery, and follow-up assessments at discharge, 1 month, and 3 months after surgery.
The primary feasibility outcomes include recruitment rate, QST completion rates, follow-up completion rates, QST-related discontinuation rate, study-related adverse events, and data completeness. The main clinical mechanistic outcome is the area of peri-incisional mechanical hyperalgesia at 48-72 hours after surgery. Secondary outcomes include acute postoperative pain intensity, pain burden over 72 hours, opioid consumption, quality of recovery, QST changes, pain-map characteristics, and chronic postsurgical pain at 3 months.
This study will not assign or modify therapeutic interventions. All anesthetic, surgical, and analgesic management will be determined by the routine clinical care team. The study is expected to provide feasibility data, preliminary effect estimates, and mechanistic information for future larger perioperative pain studies.
Detailed description
This is a single-center, prospective, observational pilot cohort study conducted in adult patients scheduled to undergo elective thoracoscopic or robotic-assisted lung resection. The study is designed to characterize perioperative pain phenotypes using standardized quantitative sensory testing (QST), incision-centered mechanical hyperalgesia pain mapping, serial pain intensity assessments, analgesic exposure, psychological and sleep-related questionnaires, and exploratory inflammatory or plasma biomarker measurements.
Eligible participants will provide written informed consent before surgery. Baseline assessments will be performed 1-3 days before surgery and will include demographic and clinical data collection, baseline pain history, psychological and sleep-related questionnaires, preoperative QST, and blood sampling. QST will assess sensory function in the surgical-side thoracic region, contralateral mirror region, and a remote control site where applicable.
During the first 72 hours after surgery, resting and movement-related numeric rating scale pain scores will be collected at prespecified time points, together with perioperative anesthetic, regional block, surgical, analgesic, and recovery-related information. Opioid consumption will be converted to morphine milligram equivalents.
At 48-72 hours after surgery, participants will undergo core postoperative QST and incision-centered mechanical pain mapping. The pain map will be generated around the incision or main port site in eight radial directions. Standardized mechanical stimulation will be applied from normal surrounding skin toward the incision, and boundary points will be marked when the participant reports a transition from normal sensation to increased pain, sharpness, burning, or abnormal discomfort. These boundary points will be connected to estimate the area of mechanical hyperalgesia.
Additional assessments will be performed before discharge, at 1 month, and at 90 ± 14 days after surgery. Follow-up assessments will evaluate persistent pain, pain intensity, pain interference, neuropathic pain features, QST changes, pain-map characteristics, quality of recovery, and exploratory blood biomarkers. Chronic postsurgical pain will be assessed at 3 months after surgery and defined as new or worsened pain related to the surgical area, persisting for at least 3 months after surgery, and not better explained by other causes.
The study will not assign any therapeutic intervention. Surgical technique, anesthetic management, regional analgesia, postoperative analgesia, chest tube management, and perioperative care will follow routine clinical practice. Key perioperative variables will be prospectively collected and considered as potential confounders in statistical analyses.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Elective Thoracoscopic or Robotic-assisted Lung Resection Cohort | – | Other: Perioperative QST and incision pain mapping assessmentAdult patients scheduled for elective thoracoscopic or robotic-assisted lung resection will be enrolled and followed prospectively from the preoperative period to 3 months after surgery. Participants will undergo observational assessments including questionnaires, quantitative sensory testing, peri-incisional mechanical hyperalgesia pain mapping, serial postoperative pain assessments, analgesic exposure recording, and exploratory blood sampling. No therapeutic intervention will be assigned by the investigators. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients scheduled to undergo elective thoracoscopic or robotic-assisted lung resection at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Key inclusion criteria (6 listed)
- Male
- Scheduled to undergo elective thoracoscopic or robotic-assisted lung resection.
- American Society of Anesthesiologists physical status I to III.
- Able to understand and communicate adequately and to complete study questionnaires independently or with assistance from study staff.
- Willing to undergo QST assessment, perioperative venous blood sampling, and postoperative follow-up.
Key exclusion criteria (7 listed)
- Definite chronic chest wall, shoulder, back, or upper limb pain with an average 2. Numeric Rating Scale score of 3 or higher during the preceding week.
- 3. Definite painful neuropathic disease or long-term use of opioids or other analgesics for more than 2 weeks.
- 4. Peripheral neuropathy, spinal cord disease, or other neurological disease that may substantially interfere with interpretation of QST results.
- 5. Severe cognitive impairment, psychiatric disorder, communication disorder, or inability to complete questionnaires and QST assessments.
- 6. Active infection, active autoimmune disease, or other disease condition that may substantially affect inflammatory protein measurements.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Perioperative QST and incision pain mapping assessmentParticipants will undergo non-invasive perioperative quantitative sensory testing and incision-centered mechanical pain mapping at prespecified time points. These assessments are observational and will not determine or modify clinical anesthesia, analgesia, or surgical management. | Other | Elective Thoracoscopic or Robotic-assisted Lung Resection Cohort |
Primary outcome
Recruitment Rate
Time frame: Baseline
Proportion of eligible patients who provide written informed consent and are enrolled in the study.
Completion Rate of Baseline Quantitative Sensory Testing
Time frame: Preoperative period, 1 to 3 days before surgery
Proportion of enrolled participants who complete the planned baseline QST assessment before surgery.
Completion Rate of Postoperative QST and Incision Pain Mapping
Time frame: 48 to 72 hours after surgery
Proportion of enrolled participants who complete the core postoperative QST assessment and incision-centered mechanical hyperalgesia pain mapping.
Completion Rate of 1-month Follow-up
Time frame: 1 month after surgery
Proportion of enrolled participants who complete the planned 1-month postoperative follow-up assessment.
Completion Rate of 3-month Pain Outcome Follow-up
Time frame: 90 ± 14 days after surgery
Proportion of enrolled participants who complete the primary 3-month postoperative pain outcome assessment.
QST-related Discontinuation Rate
Time frame: From baseline assessment to 3 months after surgery
Proportion of participants who discontinue QST or pain mapping prematurely because of pain intolerance, fatigue, anxiety, or other participant-related reasons.
Study-related Adverse Event Rate
Time frame: From baseline assessment to 3 months after surgery
Proportion of participants with study-related adverse events, including marked discomfort, transient pain exacerbation, local discomfort related to QST or pain mapping, or adverse events related to blood sampling.
Data Completeness of Key Study Variables
Time frame: From baseline assessment to 3 months after surgery
Proportion of missing data for key variables
19 secondary outcomes
Movement-related Pain Intensity During the First 72 Hours After Surgery
Time frame: 1, 6, 12, 18, 24, 32, 40, 48, 60, and 72 hours after surgery
Resting Pain Intensity During the First 72 Hours After Surgery
Time frame: 1, 6, 12, 18, 24, 32, 40, 48, 60, and 72 hours after surgery
Area of Peri-incisional Mechanical Hyperalgesia
Time frame: 48 to 72 hours after surgery
Area Under the Curve of Resting Pain Scores
Time frame: 0 to 72 hours after surgery
Area Under the Curve of Movement-related Pain Scores
Time frame: 0 to 72 hours after surgery
Cumulative Opioid Consumption
Time frame: 0 to 72 hours after surgery
Quality of Recovery-15 Score
Time frame: 72 hours after surgery and before discharge
Analgesia-related Adverse Effects
Time frame: 0 to 72 hours after surgery
Time to First Ambulation
Time frame: Perioperative
Chest Tube Duration
Time frame: Perioperative
Postoperative Length of Hospital Stay
Time frame: Perioperative
Perioperative Complications
Time frame: Perioperative
Change in Quantitative Sensory Testing Parameters
Time frame: Baseline, 48 to 72 hours after surgery, 1 month after surgery, and 90 ± 14 days after surgery
Maximum Radius of Peri-incisional Pain Map
Time frame: 48 to 72 hours after surgery, 1 month after surgery, and 90 ± 14 days after surgery
Minimum Radius of Peri-incisional Pain Map
Time frame: 48 to 72 hours after surgery, 1 month after surgery, and 90 ± 14 days after surgery
Incidence of Persistent Pain at 1 Month
Time frame: 1 month after surgery
Incidence of Chronic Postsurgical Pain at 3 Months
Time frame: 90 ± 14 days after surgery
Pain Interference at 3 Months
Time frame: 90 ± 14 days after surgery
Neuropathic Pain Features at 3 Months
Time frame: 90 ± 14 days after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Postoperative Pain
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Postoperative Pain and Chronic Postsurgical Pain, run by Tongji Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ni Zhang, Dr (8613871288490, nizhang@tjh.tjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recruitment Rate (time frame: Baseline). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.